$CRIS
CURIS INC Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000110820522000005 Filed on May 05, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$2.057M	$2.189M
YoY Change	-6.03%	-19.2%
Cost Of Revenue	$82.00K	$110.0K
YoY Change	-25.45%	-15.38%
Gross Profit	$1.975M	$2.080M
YoY Change	-5.05%	-19.38%
Gross Profit Margin	96.01%	95.02%
Selling, General & Admin	$5.673M	$4.120M
YoY Change	37.69%	14.76%
% of Gross Profit	287.24%	198.08%
Research & Development	$11.44M	$6.757M
YoY Change	69.23%	-9.58%
% of Gross Profit	578.99%	324.86%
Depreciation & Amortization	$36.00K	$40.00K
YoY Change	-10.0%	33.33%
% of Gross Profit	1.82%	1.92%
Operating Expenses	$11.44M	$6.757M
YoY Change	69.23%	-9.58%
Operating Profit	-$15.13M	-$8.800M
YoY Change	71.97%	3.75%
Interest Expense	$80.00K	$50.00K
YoY Change	60.0%
% of Operating Profit
Other Income/Expense, Net	-$976.0K	-$1.127M
YoY Change	-13.4%	-8.15%
Pretax Income	-$16.11M	-$9.930M
YoY Change	62.23%	2.27%
Income Tax
% Of Pretax Income
Net Earnings	-$16.11M	-$9.927M
YoY Change	62.27%	2.25%
Net Earnings / Revenue	-783.13%	-453.49%
Basic Earnings Per Share	-$0.18	-$0.11
Diluted Earnings Per Share	-$0.18	-$0.11
COMMON SHARES
Basic Shares Outstanding	91.65M shares	91.51M shares
Diluted Shares Outstanding	91.65M shares	91.51M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$120.7M	$156.4M
YoY Change	-22.86%	1151.2%
Cash & Equivalents	$18.47M	$111.0M
Short-Term Investments	$102.2M	$45.40M
Other Short-Term Assets	$3.426M	$3.300M
YoY Change	3.82%	120.0%
Inventory
Prepaid Expenses
Receivables	$2.060M	$2.183M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$126.1M	$161.9M
YoY Change	-22.07%	880.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$479.0K	$620.0K
YoY Change	-22.74%	56.57%
Goodwill	$8.982M	$8.982M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$0.00	$11.90M
YoY Change	-100.0%
Other Assets	$726.0K	$0.00
YoY Change		-100.0%
Total Long-Term Assets	$14.60M	$28.73M
YoY Change	-49.18%	181.76%
TOTAL ASSETS
Total Short-Term Assets	$126.1M	$161.9M
Total Long-Term Assets	$14.60M	$28.73M
Total Assets	$140.7M	$190.6M
YoY Change	-26.16%	613.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.281M	$3.429M
YoY Change	24.85%	-19.64%
Accrued Expenses	$4.586M	$2.062M
YoY Change	122.41%	19.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$891.0K
YoY Change
Total Short-Term Liabilities	$9.691M	$6.991M
YoY Change	38.62%	16.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$55.07M	$61.70M
YoY Change	-10.74%	1.15%
Total Long-Term Liabilities	$55.07M	$0.00
YoY Change		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.691M	$6.991M
Total Long-Term Liabilities	$55.07M	$0.00
Total Liabilities	$64.77M	$68.68M
YoY Change	-5.7%	2.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.100B	-$1.100B
YoY Change	0.0%	7.14%
Common Stock	$1.185B	$1.179B
YoY Change	0.52%	19.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$75.97M	$121.9M
YoY Change
Total Liabilities & Shareholders Equity	$140.7M	$190.6M
YoY Change	-26.16%	613.67%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$16.11M	-$9.927M
YoY Change	62.27%	2.25%
Depreciation, Depletion And Amortization	$36.00K	$40.00K
YoY Change	-10.0%	33.33%
Cash From Operating Activities	-$16.80M	-$13.18M
YoY Change	27.48%	46.17%
INVESTING ACTIVITIES
Capital Expenditures	$11.00K	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$3.072M	-$4.070M
YoY Change	-24.52%	-180.12%
Cash From Investing Activities	-$3.083M	-$4.071M
YoY Change	-24.27%	-184.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.648M	-$1.329M
YoY Change	24.0%	-204.07%
NET CHANGE
Cash From Operating Activities	-$16.80M	-$13.18M
Cash From Investing Activities	-$3.083M	-$4.071M
Cash From Financing Activities	-$1.648M	-$1.329M
Net Change In Cash	-$21.55M	-$18.58M
YoY Change	15.97%	541.1%
FREE CASH FLOW
Cash From Operating Activities	-$16.80M	-$13.18M
Capital Expenditures	$11.00K	$0.00
Free Cash Flow	-$16.81M	-$13.18M
YoY Change	27.56%	42.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	000-30347
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	CURIS, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3505116
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	128 Spring Street
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Building C - Suite 500
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Lexington
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02421
CY2022Q1	dei	City Area Code CityAreaCode	617
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	503-6500
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	CRIS
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18468000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40014000	USD
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	91645369	shares
CY2022Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	102185000	USD
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	75870000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2060000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3224000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3426000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3267000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	126139000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	122375000	USD
CY2022Q1	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	23964000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	479000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	505000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	726000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	726000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4413000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5749000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	8982000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	8982000	USD
CY2022Q1	us-gaap	Assets Assets	140739000	USD
CY2021Q4	us-gaap	Assets Assets	162301000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4281000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6417000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4586000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6339000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	824000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	682000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	9691000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13438000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2941000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4358000	USD
CY2022Q1	cris	Royalty Guarantees Commitments Amount Noncurrent RoyaltyGuaranteesCommitmentsAmountNoncurrent	52133000	USD
CY2021Q4	cris	Royalty Guarantees Commitments Amount Noncurrent RoyaltyGuaranteesCommitmentsAmountNoncurrent	53798000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	64765000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	71594000	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	227812500	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91645369	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	91645369	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	227812500	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91645369	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	91645369	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	916000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	916000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1183943000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1182225000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1108434000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1092325000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-451000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-109000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	75974000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	90707000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	140739000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	162301000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2057000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2189000	USD
CY2022Q1	us-gaap	Royalty Expense RoyaltyExpense	82000	USD
CY2021Q1	us-gaap	Royalty Expense RoyaltyExpense	109000	USD
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11435000	USD
CY2021Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6757000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5673000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4123000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	17190000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	10989000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15133000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8800000	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	80000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	46000	USD
CY2022Q1	cris	Non Cash Imputed Interest Expense NonCashImputedInterestExpense	1056000	USD
CY2021Q1	cris	Non Cash Imputed Interest Expense NonCashImputedInterestExpense	1173000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-976000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1127000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16109000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-9927000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91645369	shares
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-6000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91645369	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91507518	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91507518	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16109000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-9927000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-342000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-6000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16451000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9933000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	90707000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1718000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	79000	USD
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-6000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-9927000	USD
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-342000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16109000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	75974000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	130670000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1099000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	121915000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16109000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-9927000	USD
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	36000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	43000	USD
CY2022Q1	cris	Non Cash Lease Expense NonCashLeaseExpense	239000	USD
CY2021Q1	cris	Non Cash Lease Expense NonCashLeaseExpense	202000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1718000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1099000	USD
CY2022Q1	cris	Non Cash Imputed Interest Expense Net Of Imputed Interest NonCashImputedInterestExpenseNetOfImputedInterest	-18000	USD
CY2021Q1	cris	Non Cash Imputed Interest Expense Net Of Imputed Interest NonCashImputedInterestExpenseNetOfImputedInterest	-20000	USD
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-380000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-195000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1164000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-860000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	158000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2049000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3890000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2301000	USD
CY2022Q1	cris	Increase Decrease Operating Lease Liability IncreaseDecreaseOperatingLeaseLiability	-177000	USD
CY2021Q1	cris	Increase Decrease Operating Lease Liability IncreaseDecreaseOperatingLeaseLiability	-1281000	USD
CY2022Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-706000	USD
CY2021Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-3252000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16815000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13179000	USD
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	24972000	USD
CY2021Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	9071000	USD
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	21900000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	5000000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3083000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4071000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	79000	USD
CY2022Q1	cris	Payments Of Future Royalty Liability Net Of Imputed Interest PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest	1648000	USD
CY2021Q1	cris	Payments Of Future Royalty Liability Net Of Imputed Interest PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest	1408000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1648000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1329000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21546000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18579000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40740000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130426000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19194000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111847000	USD
CY2022Q1	cris	Accrued Issuance Costs AccruedIssuanceCosts	172000	USD
CY2021Q1	cris	Accrued Issuance Costs AccruedIssuanceCosts	281000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1074000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	1193000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1098000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, Inc. is a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. Throughout these Condensed Consolidated Financial Statements, Curis, Inc. and its wholly owned subsidiaries are collectively referred to as “the Company” or “Curis.”</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts its research and development programs both internally and through strategic collaborations. The Company’s clinical stage drug candidates include emavusertib, previously CA-4948, an orally available small molecule inhibitor of Interleukin-1 receptor associated kinase 4 (“IRAK4”); CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (“VISTA”) signaling pathway; fimepinostat, a small molecule that potently inhibits the activity of histone deacetylase and phosphotidyl-inositol 3 kinase enzymes; and CA-170, a small molecule antagonist of VISTA and PDL1. The Company's pre-clinical development candidates include CA-327, an orally available small molecule antagonist of PDL1 and TIM3.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a collaboration with Genentech Inc. (“Genentech”), a member of the Roche Group, under which Genentech and F. Hoffmann-La Roche Ltd (“Roche”) are commercializing Erivedge® (vismodegib), a first-in-class orally administered small molecule Hedgehog signaling pathway antagonist. Erivedge is approved for the treatment of advanced basal cell carcinoma (“BCC”).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2015, the Company entered into an exclusive collaboration agreement with Aurigene Discovery Technologies Limited (“Aurigene”) for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology, which was amended in September 2016 and February 2020. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is a party to an option and license agreement with ImmuNext. Pursuant to the terms of the option and license agreement, the Company has an option, exercisable for a specified period as set forth in the option and license agreement, to obtain an exclusive license to develop and commercialize certain VISTA antagonizing compounds, including ImmuNext's lead compound, CI-8993, and products containing these compounds in the field of oncology.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has had and may continue to have an adverse effect on the Company’s business, financial condition, results of operations, and prospects. With respect to ongoing clinical trials, the anticipated timing of enrollment and the overall timelines of the trials have experienced delays and could be further delayed to the extent the Company experiences further delays in enrollment due to the COVID-19 pandemic. The Company’s ability to collect patient data in a timely fashion may also be impacted. The Company also experienced delays in closing down its clinical trial sites related to its fimepinostat and CA-170 trials due to restrictions on non-essential workers imposed at those sites in response to COVID-19, which delayed the winding down of these trials. In addition, the Company and its collaborators, third-party contract manufacturers, contract research organizations and clinical sites could experience delays or disruptions in supply and release of product candidates and/or procuring items that are essential for its research and development activities, including, for example, raw materials used in the manufacturing of its product candidates, basic medical and laboratory supplies used in its clinical trials or preclinical studies, or animals that are used for preclinical testing, in each case, for which there may be shortages or supply chain disruptions as a result of the continuing pandemic. The Company cannot be certain what the overall impact of the COVID-19 pandemic will be on its business.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company’s business, including, but not limited to: the Company’s ability to obtain adequate financing to fund its operations; the Company’s ability to advance and expand its research and development programs; the impacts of the COVID-19 pandemic and responsive actions related thereto; the Company’s reliance on Roche and Genentech to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the ability of the Company and its wholly owned subsidiary, Curis Royalty, LLC (“Curis Royalty”) to satisfy the terms of the royalty interest purchase agreement (the “Oberland Purchase Agreement”) with TPC Investments I LP and TPC Investments II LP ("the Purchasers"), each of which is a Delaware limited partnership managed by Oberland Capital Management, LLC, and Lind SA LLC ("the Agent"), a Delaware limited liability company managed by Oberland Capital Management, LLC, as collateral agent for the Purchasers; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; the Company’s ability to comply with regulatory requirements; the Company's ability to obtain and maintain applicable regulatory approvals and commercialize any approved product candidates; and the Company’s ability to execute on its overall business strategies.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it may receive and make under its current and potential future collaborations. The results of the Company’s operations have varied and will likely continue to vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require substantial funds to maintain research and development programs and support operations. The Company has incurred net losses and negative cash flows from operations since its inception. As of March 31, 2022, the Company had an accumulated deficit of approximately $1.1 billion, and for the three months ended March 31, 2022, the Company incurred a net loss of $16.1 million and used $16.8 million of cash in operations. The Company expects to continue to generate operating losses in the foreseeable future. The Company anticipates that its $120.7 million of existing cash, cash equivalents and investments at March 31, 2022 will be sufficient to fund operations for at least 12 months from the date of filing this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control and it may be unable to raise financing when needed, or on terms favorable to the Company. If necessary funds are not available, the Company will have to delay, reduce the scope of, or eliminate some of its development programs, potentially delaying the time to market for or preventing the marketing of any of its product candidates.</span></div>
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1100000000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16100000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16800000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	120700000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5700000	USD
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates and Assumptions<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements; the estimated repayment term of the Company’s debt and related short- and long-term classification; the collectability of receivables; the carrying value of property and equipment and goodwill; and the assumptions used in the Company’s valuation of stock-based compensation and the value of certain investments and liabilities. Actual results may differ from such estimates.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 has had and may continue to have impacts on the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the continuing COVID-19 pandemic, the extent to which it has impacted and may continue to impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business responses to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of March 31, 2022 and through the date of this report. The Company’s future assessment of the magnitude and duration of the COVID-19 pandemic, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.</span></div>
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	700000	USD
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	700000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19200000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111800000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	102636000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	451000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	102185000	USD
CY2022Q1	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P0Y6M
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4400000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	99943000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	109000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	99834000	USD
CY2021	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P0Y4M24D
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2022Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1681000	USD
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3260000	USD
CY2022Q1	cris	Chemistry Manufacturing And Controls Costs ChemistryManufacturingAndControlsCosts	1557000	USD
CY2021Q4	cris	Chemistry Manufacturing And Controls Costs ChemistryManufacturingAndControlsCosts	2232000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	765000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	644000	USD
CY2022Q1	cris	License Fees LicenseFees	188000	USD
CY2021Q4	cris	License Fees LicenseFees	0	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	395000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	203000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4586000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6339000	USD
CY2020Q2	us-gaap	Long Term Debt LongTermDebt	900000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0995
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1100000	USD
CY2022Q1	cris	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-1100000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3800000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5000000.0	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P6Y
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7700000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	300000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1400000	USD
CY2022Q1	cris	Operating Lease One Time Payment Tenant Improvements OperatingLeaseOneTimePaymentTenantImprovements	1100000	USD
CY2019Q1	cris	Royalty Purchase Agreement Interest Rate RoyaltyPurchaseAgreementInterestRate	0.079
CY2019Q1	cris	Royalty Purchase Agreement Transaction Fees And Closing Costs RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts	600000	USD
CY2021Q4	cris	Royalty Purchase Agreement Liability Carrying Value RoyaltyPurchaseAgreementLiabilityCarryingValue	53798000	USD
CY2022Q1	cris	Royalty Purchase Agreement Issuance Costs Capitalized Amortization RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization	15000	USD
CY2022Q1	cris	Royalty Purchase Agreement Accretion Expense RoyaltyPurchaseAgreementAccretionExpense	1041000	USD
CY2022Q1	cris	Payments Of Future Royalty Liability PaymentsOfFutureRoyaltyLiability	2721000	USD
CY2022Q1	cris	Royalty Purchase Agreement Liability Carrying Value RoyaltyPurchaseAgreementLiabilityCarryingValue	52133000	USD
CY2022Q1	cris	Collaboration Agreement Numberof Programs Licensed CollaborationAgreementNumberofProgramsLicensed	4	program
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	151875000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	227812500	shares
CY2022Q1	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	plan
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10363769	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.80
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M28D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4313500	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.21
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	333563	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.39
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14343706	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.51
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M12D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7333000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6884853	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.31
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M3D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5247000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13445514	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.49
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y10M6D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	7193000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.62
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.13
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	0	shares
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.014
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.017
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.004
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.007
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.10
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.11
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.07
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	17600000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	0	shares
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1718000000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1099000	USD

Files In Submission

Name	View Source	Status
0001108205-22-000005-index-headers.html	Edgar Link	pending
0001108205-22-000005-index.html	Edgar Link	pending
0001108205-22-000005.txt	Edgar Link	pending
0001108205-22-000005-xbrl.zip	Edgar Link	pending
cris-20220331.htm	Edgar Link	pending
cris-20220331.xsd	Edgar Link	pending
cris-20220331_cal.xml	Edgar Link	unprocessable
cris-20220331_def.xml	Edgar Link	unprocessable
cris-20220331_htm.xml	Edgar Link	completed
cris-20220331_lab.xml	Edgar Link	unprocessable
cris-20220331_pre.xml	Edgar Link	unprocessable
cris-3312022x10qexx311.htm	Edgar Link	pending
cris-3312022x10qexx312.htm	Edgar Link	pending
cris-3312022x10qexx321.htm	Edgar Link	pending
cris-3312022x10qexx322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
CURIS INC Stock $cris

2022 Q1 Form 10-Q Financial Statement

#000110820522000005 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS CURIS INC Stock $cris

2022 Q1 Form 10-Q Financial Statement

#000110820522000005 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
CURIS INC Stock $cris